Formula I P2X7 Modulators for Inflammatory Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compounds that modulate P2X7 receptor activity, which is implicated in various inflammatory and neurological disorders.
Innovation Solution
Development of compounds of Formula (I) and their enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs, and metabolites, which act as P2X7 receptor modulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is provided for inflammatory and neurological disorders, but effective P2X7 receptor modulation is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying chemical structures (Formula I compounds with various substituents R1-R6, Ra-Re) to optimize P2X7 receptor binding affinity and modulatory activity. By systematically varying chemical parameters such as substituent types, positions, and configurations, the invention achieves effective P2X7 modulation that current therapies lack.
2Adaptability or versatility
If new P2X7 modulator compounds are developed, then P2X7 receptor activity is effectively modulated, but therapeutic application for specific diseases requires further validation
Solution Approach 1:
The patent applies preliminary action by conducting extensive in vitro and in vivo characterization of Formula I compounds before clinical application. The invention includes detailed pharmacological profiling, mechanism of action studies, and preclinical efficacy models to validate therapeutic potential for specific diseases such as inflammatory and neurological disorders, thereby reducing future clinical development risks.
Data Source
AI summary
The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof:The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.